Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD).

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Paroxetine; Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Male or female aged 18 to 65 years;

• A diagnosis of generalized anxiety disorder;

• Absence of current episode of major depression.

Exclusion Criteria:

• The presence or history of schizophrenia and other psychotic disorders;

• Hypertension;

• A current diagnosis of cancer, unless in remission for at least 5 years